跳至主要内容
临床试验/NCT06539052
NCT06539052尚未招募不适用

A Model to Improve the Screening and Linkage to Care of HDV Infection in Migrant Living in Southern Italy Taking Advantage of HDV Reflex Testing: MIGrant Reflex Test HDV (MIGRED) Project

University of Campania Luigi Vanvitelli0 个研究点目标入组 7,500 人开始时间: 2024年12月20日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
7,500
主要终点
Detection rate of HDV RNA.

研究概览

简要总结

Our research team has executed a robust strategy to improve viral hepatitis detection and linkage to care in migrants, contributing to the improvement of knowledge on the clinical and virological future of viral hepatitis in this population difficult to reach and manage. Our hypothesis is that the extension of our model to three other large university clinical centers operating in southern Italy and the use of HDV reflex testing for HBsAg-positive subjects will allow the implementation of knowledge on prevalence of HDV in migrants living in southern Italy and coming from HDV endemic areas. Precisely, the investigators will involve the Department of Infectious Diseases of the University of Bari, that of the University of Catanzaro and that of the University of Palermo with expertise in the management of infectious diseases in the migratory context and with whom the investigators have previously collaborated in other areas.

It is expected to enroll at least 7500 patients. The project will last 18 months.

Diagnosis and treatment of HDV infection in migrants will reduce the circulation of HDV in low endemic regions such as our region. Follow-up of HDV-infected individuals and reducing the rate of new infections among migrants will reduce the number of people who will experience complications related to HDV infection, such as decompensated liver cirrhosis and carcinoma hepatocellular. All this will determine benefits for the Italian public health system.

详细描述

Hepatitis D virus (HDV) infection, which occurs only in subjects with hepatitis B infection, increases the risk of hepatocellular carcinoma (HCC), decompensated cirrhosis, and mortality compared to hepatitis B virus (HBV) mono-infection. Therefore, estimates the prevalence of HDV infection and disease burden are essential to investigate models to find coinfected individuals more effectively and in an efficient way. Diagnosis of HDV allows to reduce the risk of disease progression and prevent HDV transmission, allows to intervene with antiviral treatment and allows to follow-up HDV positive subjects with ultrasound for HCC surveillance [1-4]. The data on the prevalence of HDV worldwide is unclear, with an estimated prevalence of anti-Delta-positivity in HBsAg positive patients of 4.5%-13% and an estimated number of anti-Delta-subjects of 8,2-60 million [5-6]. These variable estimates may be due in part to the fact that not all HBsAg-positive subjects were screened for anti-Delta. All the strategies for the improvement of the rate of screening of HBsAg-positive-subjects may improve the knowledge on the prevalence of HDV worldwide, especially in the high endemic populations. Recently, one of the strategies that has shown good results in the identification of HDV infection is the use of anti HDV reflex testing [4]. However, HDV is highly endemic in several African countries and in some countries in South America, the Middle East, central and northern Asia, and Eastern Europe [7]. A systematic review of the prevalence of HDV infection in HBsAgpositive populations in sub Saharan Africa showed a pooled seroprevalence in HBsAg-positive general populations and in patients with liver disease of 7.33% and 9.57%, respectively in western Africa, of 25.6% and 37.8% in central Africa, and of 0.05% in the general populations of eastern and southern Africa [8]. In Italy the prevalence of HDV infection in HBsAg-positive subjects ranges from 9.7 to 12%, with evidence of an increasing prevalence of HDV infection in the immigrant population in recent years [9-15]. Probably, this happened because for its geographical position in the center of the Mediterranean Sea, Italy has been greatly involved in immigration from Africa, in particular from sub-Saharan Africa, and also from Asia and Eastern Europe; for example from January 2023 until September 2023 in Italy are arrived about 128,000 migrants and most of them coming from Sub-Saharan Africa and East Europe, prevalence (Situation Mediterranean Situation (unhcr.org), all areas with high HDV prevalence, The majority of these migrants arrived, as first site, in Southern Italy, Sicily, Apulia, Calabria and Campania. However, few data have been published so far on the prevalence of HDV infection in immigrant populations in Western countries and in Italy and even poorer is the information on the virological and clinical aspects of HDV infection in this population.

Our research group performed a valid strategy to improve the detection for viral hepatitis and the link to care in migrants, contributing to the improvement of knowledge on clinical and virological futures of viral hepatitis in this population difficult to reach and to manage [1-3]. Our hypothesis is that the extension of our model in other three large university clinical centers operating in southern Italy and the use of the HDV reflex testing for HBsAg-positive individuals will allow to implement the knowledge on the HDV prevalence in migrants living in southern Italy and coming from endemic areas for HDV. Precisely, the investigators will involve the Department of Infectious Diseases of the University of Bari, that of the University of Catanzaro and that of the University of Palermo with expertise in the management of infectious diseases in migrant and with which the investigators previously collaborated in other setting.The investigators performed a retrospective and prospective multicenter project lasting 18 months involving the 4 largest University clinical Centers for Infectious Diseases (ID) in southern Italy:

Departments of ID of the University of Napoli L.Vanvitelli (project coordinator), of the University of Bari, of the University of Catanzaro and of the University Palermo.

At this time they are not involved in any other projects involving screening and linkage to care of HDV infection.

Each of these tertiary center is associated to 1st level clinical centers, that are centers of general practice clinics attended mainly by migrants for low back pain, headache, itching, cough, hypertension and allergy symptoms. These first-level centers are linked with the Italian humanitarian organizations which welcome needy migrants. The organization of these clinics involves the presence of a physhycian expert in the management of infectious diseases in migrants, a nurse and a cultural mediator. This last figure is fundamental in explaining the epidemiological, clinical and collective health reasons that make it necessary to screen for hepatitis viruses which are endemic in their areas of origin.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All migrants, documents or undocumented migrants, and low-income refugees belonging to the infectious disease centers of the university centers participating in the project will be enrolled. aged > 18 years subjects who have given informed consent to carry out blood sampling and for the collection of epidemiological data

排除标准

  • all migrants < 18 years of age who have not given informed consent for the collection of the blood sample and/or epidemiological data.

结局指标

主要结局

Detection rate of HDV RNA.

时间窗: 1 month

quantitative Test RT-PCR (Reverse Transcription Polymerase Chain Reaction).

Distribution of clinical (e.g., ALT/AST levels, liver fibrosis) features based on anti-Delta positivity.

时间窗: 1 month

Measuring instrument: Standardized laboratory tests (blood tests, virological tests) and diagnostic tools (ultrasounds, fibroscans).

Distribution of Virological Features

时间窗: 1 month

This measure will assess how virological features (e.g., HBV and HDV viral load) are distributed among anti-Delta positive subjects based on HDV-RNA positivity. * Measurement tool: Laboratory testing for HDV-RNA using RT-PCR (Reverse Transcription Polymerase Chain Reaction) and virological tests for HBV viral load. * Data Aggregation: Data will be aggregated by viral load and presented in frequency tables and descriptive statistics.

Prevalence of anti-Delta positivity in different demographic categories.

时间窗: 1 month

Demographic questionnaires

Distribution of clinical features

时间窗: 1 month

This measure will assess how clinical features (e.g., ALT/AST levels, liver fibrosis) are distributed among anti-Delta positive subjects based on HDV-RNA positivity. * Measurement Tool: Standardized clinical examinations, including blood tests for ALT/AST levels and liver fibrosis assessments via fibroscan. * Data aggregation: Data will be aggregated for each clinical parameter and presented in frequency tables and descriptive statistics.

Number of subjects evaluated for therapy.

时间窗: 1 month

Clinical patient records and standardized medical assessments

Number of HBsAg positive subjects who are also HIV Ab positive and/or HCV Ab positive.

时间窗: 1 month

Enzyme-Linked Immunosorbent Assay (ELISA) test for HIV Ab and HCV Ab.

Number of anti-Delta-positive subjects connected to tertiary services.

时间窗: 1 month

Clinical recording of referrals and confirmation of successful connection through digital medical records

Assessment of virological (e.g., HBV viral load) features

时间窗: 1 month

This outcome measure will assess HBV viral load in anti-Delta positive subjects and how it varies with HDV-RNA positivity. HBV viral load will be quantified using specific and standardized virological tests. Measurement tool: Laboratory testing for HBV viral load, such as polymerase chain reaction (PCR) quantification. Data aggregation: Viral load data will be aggregated and presented as mean viral load, median, and distribution of viral loads in HDV-RNA positive subjects. Descriptive statistics will include minimum, maximum, means, and standard deviations

Distribution of demographic characteristics (age, sex, geographical origin)

时间窗: 1 month

This measure will assess how demographic characteristics (age, sex, geographic origin) are distributed among anti-Delta positive subjects based on HDV-RNA positivity. * Measurement tool: Demographic questionnaires completed by participants. * Data aggregation: Data will be aggregated by age, gender, and geographic origin, and presented in frequency tables and descriptive statistics.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nicola Coppola

Chief of Infectoius Diseases Unit

University of Campania Luigi Vanvitelli

相似试验